Bacitracin is a proteolytic inhibitor which interacts with the intracellular processing of insulin. Its effects on pyruvate, fatty acid and amino acid metabolism were examined in rat hepatocyte suspensions. Bacitracin (0.25-1.0mM) increased the oxidation of 11-14Cipyruvate by 50-70% and presumably therefore increased the flux through pyruvate dehydrogenase. This was found both in the presence of extracellular Ca2+ and in its absence, but not in the presence of 2mM-2-chloropropionate, which inhibits pyruvate dehydrogenase kinase. Insulin did not further stimulate [1-14Clpyruvate oxidation in the presence of 1mM-bacitracin. Bacitracin decreased 14C02 formation from [2-'4Clpyruvate (20-40%) and (U-14Clpalmitate (30-70%), suggesting a decreased flux through the tricarboxylic acid cycle. Fatty acid oxidation before acetyl-CoA formation was also decreased. Bacitracin decreased the incorporation of label from 13Hlleucine into protein in the absence of insulin, but not in its presence.
label from 13Hlleucine into protein in the absence of insulin, but not in its presence.
Bacitracin is commonly used in studies on insulin action. Our results suggest that in such studies the effects noted may be related not only to an interaction of bacitracin with the intracellular processing of insulin but also to direct metabolic effects of bacitracin independent of insulin.
Bacitracin, a cyclic polypeptide derived from Bacillus licheniformis, is widely used as an antibiotic and as a proteolytic inhibitor to inhibit the degradation of insulin and glucagon in studies on hormone-receptor binding and action (Makinen,1972; Desbuquois et al., 1974; Carpentier et al., 1979; Dolais-Kitabgi et al., 1981) . It has been used primarily to inhibit the extracellular degradation of polypeptide hormones in studies with isolated plasma membranes and intact hepatocyte and adipocyte preparations. However, it has more recently been shown to affect the intracellular processing of insulin, in studies with freshly isolated hepatocytes (Juul & Jones, 1982) and cultured foetal hepatocytes (Plas & Desbuquois, 1982) .
Studies with isolated rat adipocytes (Larner et al., 1982) showed that, at concentrations up to 5 mM, bacitracin prevented insulin degradation, but did not block insulin action. The latter was blocked at 9 mM-bacitracin. In rat adipocytes, bacitracin inhibited cyclic AMP-induced lipolysis, and it was suggested that bacitracin can be used to study lipolysis in the absence of other insulin-like effects (Heckemeyer et al., 1982) . There (Kirkby, Liverpool, U.K.) . All other chemicals were from BDH Chemicals (Poole, Dorset, U.K.). The bovine serum albumin was defatted and dialysed as described by Chen (1967 (Seglen, 1976) . The incubation medium was a modified Krebs-Henseleit (1932) buffer containing lOmM-NaHCO3 The final L-leucine concentration was 0.4mm. The protein was precipitated with trichloroacetic acid and treated as described by Clark & Hansen (1980) . Adenine nucleotides and ketone bodies were assayed in the neutralized HC104 extracts by enzymic methods (ADP and AMP, Adam, 1963; ATP, Lamprecht & Trautschold, 1963; acetoacetate and D-3-hydroxybutyrate, Williamson et al., 1962 (Stucki & Walter, 1972) .
In the present study, bacitracin (0.25-1.0 mM) increased the formation of 14CO2 from [1-14C1-pyruvate by 50-70% (Table 1) . Bacitracin has been suggested to increase the transport of bivalent ions (Heckemeyer et al., 1982 ). An increased uptake of extracellular Ca2+ would be expected to lead to influx of Ca2+ into the mitochondria and activation of pyruvate dehydrogenase by stimulation of the Ca2+-sensitive phosphatase (Denton et al., 1972) . In the absence of bacitracin. insulin (0.85-8.5 nM) increased (P<0.05) the oxidation of 11-14Clpyru-vate by 12-16% (Fig. 1) . In the presence of 1.OmM-bacitracin, insulin did not further stimulate the oxidation of [1-14Clpyruvate (Fig. 1) .
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2-Chloropropionate stimulates pyruvate dehydrogenase by inhibiting pyruvate dehydrogenase kinase (Whitehouse et al., 1974) . The stimulatory effects of bacitracin and 2-chloropropionate on 1-14Clpyru-vate oxidation were not additive (Fig. 2) Metabolic rates expressed as the formation of "4C02 from 14C-labelled substrates may represent an underestimate of the oxidation of substrate, because the "4CO2 generated can be reincorporated into intermediary metabolites via exchange reactions (Tomera et al., 1982) . In the present study, the effects of bacitracin on the incorporation of 14C02 into acid-soluble metabolites was examined in order to establish whether the observed effects of bacitracin on the accumulation of 14C02 from 14C-labelled substrates result from changes in substrate oxidation or C02 reincorporation. The hepatocytes were incubated with H"4CO3-, assuming that HC03-and C02 equilibrate as a single pool. After termination of the incubation with HC104, the liberated CO2 was absorbed in Hyamine. Recovery of radioactivity in the Hyamine fraction and acid-soluble (non-volatile metabolites) supernatant was >95%. The radioactivity in the pellet (HCl04-insoluble) was negligible. The radioactivity incorporated into metabolites non-volatile in acid was linear with time during a 60 min time course. The percentage of HC03-plus CO2 from the medium that was incorporated into acid-soluble metabolites by a cell concentration of 1.3 x 106cells/ ml was 1.3% at 20min, 3.2% at 40min and 4.5% at 60min. The total rate of 14CO2 fixation calculated from the radioactivity in the non-volatile acid-soluble fraction and the initial specific radioactivity of the HCO3-plus CO2 was 43.7±5.6,umol/h per g wet wt. of hepatocytes (mean + S.E.M., n = 7). This assumes that the total concentration and specific radioactivity of HCO3-plus CO2 remained constant during the incubation and that the extracellular CO2 equilibrates with the CO2 in the cytosolic and mitochondrial compartments. The linearity of the time course and the low percentage of total label (<5%) incorporated into non-volatile compounds support the first assumption. The validity of the assumption that extracellular and intracellular CO2 equilibrate (Tomera et al., 1982) remains to be verified. Bacitracin (0.5-1.OmM) resulted in a small but significant increase (6-11%) in the incorporation of "4CO2 into non-volatile acid-soluble metabolites (Table 3 ). The finding that less than 5% of the HCO3-plus CO2 in the medium was incorporated into acid-soluble metabolites/h per 106 cells (Table 3) (,umol/g wet wt.; means+S.E.M. for n=3)]. This suggests that there was no leakage of adenine nucleotides from the cell and is consistent with the observation that the metabolic effects of bacitracin on adipocytes were reversible on removal of bacitracin (Heckemeyer et al., 1982) , implying that it did not cause permanent cell damage.
In hepatocytes from fed rats incubated with 0.3 mM-palmitate, bacitracin decreased the [3-hydroxybutyratel/[acetoacetatel ratio (control, 0.73 + 0.04; 0.25 mM-bacitracin, 0.61 + 0.02; 0.50mM-bacitracin, 0.60+0.04; 1.OmM-bacitracin, 0.58+0.06; means+S.E.M. for n=3) suggesting a more oxidized mitochondrial NADH/NAD+ redox state. This was not associated with a decrease in ketone-body formation [control, 34.8 + 7.7; 0.25 mM-bacitracin, 38 .7 + 10.9; 0.50mM-bacitracin, 40.7 + 6.4; 1.0 mM-bacitracin, 44.6 + 6.4 (,umol of ketone bodies formed/h per g wet wt. of hepatocytes)l. However, a decrease in ketone-body formation with bacitracin was observed with hepatocytes from 24h-starved rats. The latter may be due to inhibition of fatty acid oxidation (Table 2) , whereas the failure to observe a decrease in ketone-body formation in hepatocytes from fed rats may be the result of increased acetyl-CoA formation via pyruvate dehydrogenase. An increase in ketone-body formation from pyruvate is also observed with dichloroacetate (Agius & Vaartjes, 1982) , which activates pyruvate dehydrogenase (Whitehouse et al., 1974) .
Effects of bacitracin and insulin on [3Hlleucine incorporation into protein
When hepatocytes were incubated with L-[4,5-3Hlleucine, in the absence of insulin, bacitracin decreased the incorporation of label into protein (Fig. 3) . Insulin had no effect on the incorporation of label in the absence of bacitracin. In the combined presence of bacitracin and insulin the incorporation was higher than in the presence of insulin alone (Fig.  3) . In the present study, the final L-leucine concentration was 0.4 mm. Using higher concentrations of leucine (10-20mM), Clark & Hansen (1980) showed that insulin increased 3H]ileucine incorporation into protein. It was assumed that the intracellular and extracellular specific radioactivities of leucine were equal and that the effect of insulin was on protein synthesis. In the present study the incorporation of 3H label into protein is expressed as the rate of leucine incorporation into protein, assuming that the leucyl-tRNA specific radioactivity is equal to the specific radioactivity of the extracellular leucine (Khairallah & 1976). It should be emphasized. however, that a change in label incorporation could arise from a change in specific radioactivity of the intracellular 3H-labelled leucine or leucyl-tRNA rather than a change in protein synthesis. Thus the increased incorporation of label in the combined presence of insulin and bacitracin may result from increased protein synthesis and/or an increased intracellular specific radioactivity because of inhibition of protein degradation or increased amino acid uptake.
Conclusions
Metabolic effects of bacitracin. Bacitracin inhibits cyclic AMP-induced lipolysis in rat adipocytes (Heckemeyer et al.. 1982) , and it increases glucose incorporation into glycogen in cultured foetal hepatocytes (Plas & Desbuquois, 1982) . The present study shows that bacitracin, at concentrations currently used to inhibit hormone degradation, increases the flux through pyruvate dehydrogenase but decreases tricarboxylic acid-cycle activity. These changes were associated with a more oxidized mitochondrial redox state, but no change in total cellular adenine nucleotides. It is unlikely that these effects of bacitracin are secondary to an increase in plasma-membrane permeability to Ca2+ (Heckemeyer et al.. 1982). since an increased oxidation of [l1-4Clpyruvate was observed also in the absence of extracellular Ca2+. However, other ionic changes cannot be excluded. A key question is what is the primary site(s) of action of bacitracin. The more oxidized mitochondrial redox state may account for the activation of pyruvate dehydrogenase by decreased end-product inhibition and inactivation of the kinase which converts the enzyme into its inactive phosphorylated form.
Effects on insulin action. In the present study, the stimulatory effect of bacitracin on [1-14Clpyruvate oxidation was larger than that of insulin, and in the presence of bacitracin insulin caused no further stimulation. In cultured hepatocytes (Plas & Desbuquois, 1982) , the effect of insulin on [14Clglucose incorporation into glycogen was decreased in the presence of 2mM-bacitracin. Higher concentrations of bacitracin (9mM) were necessary to block the action of insulin on glucose oxidation in rat adipocytes (Larner et al., 1982) . Effects of bacitracin on insulin action have been interpreted in terms of: (i) inhibition of extracellular degradation of hormone and increased binding (Desbuquois et al., 1974) ; (ii) an interaction of bacitracin with the intracellular degradation of insulin (Juul & Jones, 1982; Plas & Desbuquois, 1982) ; (iii) the postreceptor events in insulin action may involve the generation of a low-molecular-weight peptide, and bacitracin may inhibit the formation of the peptide (Larner et al., 1982) . Since bacitracin exerts marked effects (in the absence of added hormones) on the metabolism of pyruvate and fatty acids at concentrations below 1 mM, the block of insulin action at millimolar bacitracin concentrations may be related to an effect of bacitracin at the level of the metabolic pathway rather than an interaction with the intracellular processing of insulin. Although bacitracin suppressed the effects of insulin on [1-_4C]pyruvate oxidation in the present study and glucose incorporation into glycogen in cultured hepatocytes (Plas & Desbuquois, 1982) , it increased the incorporation of 13Hlleucine into protein in the presence of insulin, but not in its absence. This might suggest an intracellular interaction of bacitracin and insulin. Whatever the mechanism of action, the metabolic effects of bacitracin need also to be considered in studies involving bacitracin and insulin action.
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